AR114418A1 - Compuesto cíclico de metilactama y su utilización farmacéutica - Google Patents

Compuesto cíclico de metilactama y su utilización farmacéutica

Info

Publication number
AR114418A1
AR114418A1 ARP190100503A ARP190100503A AR114418A1 AR 114418 A1 AR114418 A1 AR 114418A1 AR P190100503 A ARP190100503 A AR P190100503A AR P190100503 A ARP190100503 A AR P190100503A AR 114418 A1 AR114418 A1 AR 114418A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical use
methylactam
cyclic compound
pharmaceutical
compound
Prior art date
Application number
ARP190100503A
Other languages
English (en)
Spanish (es)
Inventor
Yoshinori Tamatani
Tomoya Miura
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR114418A1 publication Critical patent/AR114418A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP190100503A 2018-03-01 2019-02-28 Compuesto cíclico de metilactama y su utilización farmacéutica AR114418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01

Publications (1)

Publication Number Publication Date
AR114418A1 true AR114418A1 (es) 2020-09-02

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100503A AR114418A1 (es) 2018-03-01 2019-02-28 Compuesto cíclico de metilactama y su utilización farmacéutica

Country Status (21)

Country Link
US (4) US11014910B2 (cg-RX-API-DMAC7.html)
EP (1) EP3760624A4 (cg-RX-API-DMAC7.html)
JP (3) JP7206132B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795351B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757877B (cg-RX-API-DMAC7.html)
AR (1) AR114418A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019227770B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016788A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087859A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002199A1 (cg-RX-API-DMAC7.html)
IL (1) IL276311B2 (cg-RX-API-DMAC7.html)
MA (1) MA52427A (cg-RX-API-DMAC7.html)
MX (1) MX2020009070A (cg-RX-API-DMAC7.html)
MY (1) MY205197A (cg-RX-API-DMAC7.html)
PE (1) PE20210123A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551340A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420037B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007120UA (cg-RX-API-DMAC7.html)
TW (1) TWI805699B (cg-RX-API-DMAC7.html)
WO (1) WO2019168096A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004600B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2332412C2 (ru) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2064222B1 (en) * 2007-04-02 2014-05-07 Theracos, Inc. Benzylic glycoside derivatives and methods of use
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途

Also Published As

Publication number Publication date
MX2020009070A (es) 2020-10-08
SA520420037B1 (ar) 2024-07-28
US20220064148A1 (en) 2022-03-03
CA3087859A1 (en) 2019-09-06
US20240174646A1 (en) 2024-05-30
TW202000660A (zh) 2020-01-01
CN111757877A (zh) 2020-10-09
MA52427A (fr) 2021-01-06
IL276311A (en) 2020-09-30
BR112020016788A2 (pt) 2021-01-12
JP2025026615A (ja) 2025-02-21
RU2020131756A (ru) 2022-03-28
CN111757877B (zh) 2023-10-27
CL2020002199A1 (es) 2020-12-18
MY205197A (en) 2024-10-07
AU2019227770A1 (en) 2020-07-09
KR102795351B1 (ko) 2025-04-16
JP2023026566A (ja) 2023-02-24
PH12020551340A1 (en) 2021-05-31
WO2019168096A1 (ja) 2019-09-06
US20190352284A1 (en) 2019-11-21
SG11202007120UA (en) 2020-08-28
AU2019227770B2 (en) 2023-10-05
ZA202004600B (en) 2022-03-30
US20260152490A1 (en) 2026-06-04
JP2019151627A (ja) 2019-09-12
IL276311B2 (en) 2023-10-01
IL276311B1 (en) 2023-06-01
EP3760624A4 (en) 2021-11-03
EP3760624A1 (en) 2021-01-06
US11014910B2 (en) 2021-05-25
PE20210123A1 (es) 2021-01-19
KR20200128033A (ko) 2020-11-11
TWI805699B (zh) 2023-06-21
JP7206132B2 (ja) 2023-01-17

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
ECSP18082774A (es) Derivados aromáticos de sulfonamida
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
BR112015030399B8 (pt) Derivados heterocíclicos, uso dos referidos derivados e composição farmacêutica para a prevenção ou tratamento de doenças associadas com a ativação da proteína stat3
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
CL2021002480A1 (es) Agonistas compuestos macrocíclicos como de sting
BR112021023927A2 (pt) Composto, e, composição farmacêutica
WO2016068580A3 (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2019012522A (es) Compuestos y metodos terapeuticos.
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas

Legal Events

Date Code Title Description
FG Grant, registration